NDC 63323-562-41 - Bivalirudin
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 63323-562
- Requested NDC
- 63323-562-41
- Package NDCs from labels
- 63323-562-41, 63323-562-15, 63323-562-10
- Manufacturer
- Fresenius Kabi USA, LLC
- Effective date
- 2025-08-27
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Bivalirudin - Fresenius Kabi USA, LLC | Fresenius Kabi USA, LLC | 2025-08-27 | HUMAN PRESCRIPTION DRUG LABEL |
| Bivalirudin - Fresenius Kabi USA, LLC | Fresenius Kabi USA, LLC | 2025-05-08 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 63323-562-10 | Bivalirudin | 1 in 1 VIAL, SINGLE-USE | INJECTION, POWDER, LYOPHILIZED, | 1 | 5 | |
| 63323-562-10 | Bivalirudin | 10 in 1 CARTON | INJECTION, POWDER, LYOPHILIZED, | 10 | 5 | |
| 63323-562-15 | Bivalirudin | 10 in 1 CARTON | INJECTION, POWDER, LYOPHILIZED, | 10 | 4 | |
| 63323-562-41 | Bivalirudin | 1 in 1 VIAL, SINGLE-USE | INJECTION, POWDER, LYOPHILIZED, | 1 | 4 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 63323-562 | BIVALIRUDIN INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [FRESENIUS KABI USA, LLC ] | 4 | Current NDC, Legacy NDC, 2 package rows | 20210123_af943fa0-ab0f-4b62-9ff0-54ee24cdb772.zip |
| 63323-562 | BIVALIRUDIN INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [FRESENIUS KABI USA, LLC ] | 3 | Current NDC, Legacy NDC, 2 package rows | 20210616_50975be1-6d1f-497c-b989-1825a0fae1a7.zip |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 63323-562-10 | EA - Each | 63323-562 | 11895a43-546a-476a-9a2f-dbbd05c67031 | 1 | 2016-11-08 |
| 63323-562-15 | EA - Each | 63323-562 | 430d6d8d-936f-4775-a879-52ebbe87a83e | 1 | 2018-01-12 |
| 63323-562-41 | EA - Each | 63323-562 | 46d173a0-2449-4296-b8c6-4f9ca6b95bf6 | 1 | 2018-01-12 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Mannitol | MANNITOL | B. Braun Medical Inc. | d12cc802-b538-4065-a264-f474ff3b3043 | 2023-08-15 | Warnings, Adverse reactions | 3OWL53L36A |
| Mannitol | MANNITOL | Fresenius Kabi USA, LLC | c395e13d-6ea1-4104-8b37-669cfb982f04 | 2023-03-16 | Warnings, Adverse reactions | 3OWL53L36A |
| bivalirudin | BIVALIRUDIN | Slate Run Pharmaceuticals, LLC | 5d9a45c6-e234-4d56-9132-5e24e65852e6 | 2021-06-09 | Warnings, Adverse reactions | 308769 TN9BEX005G |
| BIVALIRUDIN | BIVALIRUDIN | Meitheal Pharmaceuticals Inc. | 4119b710-ef30-4e3e-b99a-38e42b4b3fca | 2021-06-08 | Warnings, Adverse reactions | 308769 TN9BEX005G |
| bivalirudin | BIVALIRUDIN | Sandoz Inc | ce56f806-7845-429d-a1ce-c2dbf79b22eb | 2019-09-30 | Warnings, Adverse reactions | 308769 TN9BEX005G |
| Bivalirudin | BIVALIRUDIN | Dr. Reddy's Laboratories Limited | 19beb2ae-6064-3c24-fe50-0cee86896979 | 2019-07-16 | Warnings, Adverse reactions | 308769 TN9BEX005G |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.